Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00945009 · ClinicalTrials.gov registry record · Phase 3

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

A Phase 3 study of Stage III Kidney Wilms Tumor and Rhabdoid Tumor of the Kidney, sponsored by Children's Oncology Group.

Active
Registry status
Phase 3
Development phase
249
Enrollment target
20
Study locations

NCT00945009: Active Phase 3 study of Stage III Kidney Wilms Tumor and Rhabdoid Tumor of the Kidney, sponsored by Children's Oncology Group.

NCT00945009 is a Phase 3 study of Stage III Kidney Wilms Tumor and Rhabdoid Tumor of the Kidney that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 249 participants, below the 486-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00945009, a Phase 3 study of Stage III Kidney Wilms Tumor and Rhabdoid Tumor of the Kidney, is active but no longer recruiting, sponsored by Children's Oncology Group.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
249 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

Primary Outcome

Probability of no relapse, secondary malignancy, or death whichever occurs first

Interventions

  • RADIATION Radiation Therapy
  • DRUG Doxorubicin Hydrochloride
  • PROCEDURE Therapeutic Conventional Surgery
  • BIOLOGICAL Dactinomycin
  • DRUG Vincristine Sulfate

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • Loma Linda University Medical Center - Loma Linda
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • Rady Children's Hospital - San Diego - San Diego
  • UCSF Medical Center-Parnassus - San Francisco
  • UCSF Medical Center-Mission Bay - San Francisco

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham

Arizona

  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Arkansas

  • Arkansas Children's Hospital - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Colorado

  • Children's Hospital Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 249 participants
Start Date 2009-07-13
Phase Phase 3
Children's Oncology Group

342 total trials

What the registry record for NCT00945009 still lists

NCT00945009 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (49% lower).

The record links to 10 conditions, with Stage III Kidney Wilms Tumor appearing as the primary indexed condition, and to 5 interventions - of which Radiation Therapy is the first listed.

NCT00945009 names 20 study sites across 5 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00945009 about?

NCT00945009 is a clinical study titled "Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor". This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spre...

What is the current status of trial NCT00945009?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2009-07-13.

What conditions does trial NCT00945009 study?

This clinical trial studies the following conditions: Stage III Kidney Wilms Tumor, Rhabdoid Tumor of the Kidney, Stage II Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage I Kidney Wilms Tumor.

What interventions are being tested in trial NCT00945009?

The interventions under investigation include: Radiation Therapy (RADIATION), Doxorubicin Hydrochloride (DRUG), Therapeutic Conventional Surgery (PROCEDURE), Dactinomycin (BIOLOGICAL), Vincristine Sulfate (DRUG).

Who is sponsoring clinical trial NCT00945009?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00945009 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Kidney Wilms Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04628767 · 249 participants · Phase 2

    Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

  • NCT05834907 · 249 participants · NA

    Hands and Hearts Together

  • NCT06067555 · 249 participants · Early Phase 1

    Intradermal Influenza Vaccination

  • NCT06588478 · 249 participants · Phase 2

    A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00945009, the US trial registry maintained by the National Library of Medicine. NCT00945009 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.